Side-by-side · Research reference

DihexavsDSIP

Side-by-side comparison across mechanism, dosage, evidence, side effects, administration, and stack synergies. Citations on every claim where available.

AAnimal-StrongHUMAN-REVIEWED7/28 cited

BHuman-MechanisticAUTO-DRAFTED8/36 cited

Dihexa

Angiotensin IV Analogue · Pre-Clinical

Pre-clinicalDevelopment stage

Rodent onlyEvidence basisBenoist 2014

HGF/c-MetTarget systemWright 2015

Not established — animal studies only

DSIP

Sleep modulator · Anti-stress

100–200 mcgPer doseSchneider 1986

HumanMechanisticSchneider 1986

HoursHalf-life (est)

SQ · Pre-sleep · Daily during cycle

01Mechanism of Action

Parameter

Dihexa

DSIP

Primary target

c-Met receptor (HGF receptor tyrosine kinase)

Multiple — modulates HPA axis + thalamic delta-wave generation (proposed)Schneider 1986

Pathway

HGF/c-Met receptor activation → downstream signaling cascade → synaptogenesis and dendritic arborization

Reduced cortisol/ACTH + enhanced delta-wave EEG activity → improved sleep onset + depthSchneider 1986

Downstream effect

Induction of dendritic arborization, synapse formation, neurogenesis, and neuroprotection in rodent models

Faster sleep onset, increased delta sleep, reduced stress response, possible anxiolytic effectSchneider 1986

Feedback intact?

—

Origin

Small-molecule angiotensin IV analogue designed to activate HGF/c-Met systemWright 2015

Endogenous peptide first isolated from rabbit blood during delta sleep; synthesised exogenouslySchneider 1986

Antibody development

—

02Dosage Protocols

Parameter

Dihexa

DSIP

Human dosing

Not established — no human trials

—

Animal studies

Mouse/rat models only — dosing not translatable to humans

—

Evidence basis

Pre-clinical / Rodent models

Human-mechanistic + early clinicalSchneider 1986

Clinical status

No Phase 1, 2, or 3 trials published

—

Standard dose

—

100–200 mcg SQ pre-sleepSchneider 1986

Frequency

—

Once daily, pre-sleep

Lower / starter dose

—

50 mcg pre-sleep

Duration

—

8–12 weeks per cycle

Reconstitution

—

Bacteriostatic water

Timing

—

30–60 min pre-sleep

Half-life

—

Short plasma; CNS effects last hours

04Side Effects & Safety

Parameter

Dihexa

DSIP

Human safety data

None available — no human clinical trials

—

Theoretical c-Met risks

c-Met receptor activation has been implicated in tumorigenesis; unknown cancer risk profile

—

Pre-clinical tolerability

Not systematically reported in available studies

—

Injection site reaction

—

Mild irritation

Drowsiness

—

Expected effect (intentional)

Vivid dreams

—

Anecdotally reported

Long-term safety

—

Limited modern RCT data

Pregnancy / OB

—

Avoid

Absolute Contraindications

Dihexa

·Not approved for human use — research compound only

DSIP

·Pregnancy / breastfeeding
·Concurrent CNS-depressant therapy without supervision

Relative Contraindications

Dihexa

·Theoretical contraindication: active or history of malignancy (c-Met pathway involvement in cancer)

DSIP

·Severe sleep apnoea (untreated)
·Concurrent benzodiazepine / opioid use

05Administration Protocol

Parameter

Dihexa

DSIP

1. Human administration

No established protocol. Dihexa has not been tested in human subjects. Animal studies used various routes (typically subcutaneous or intraperitoneal in rodents) not translatable to clinical use.

Add 1–2 mL bacteriostatic water to vial.

2. Legal status

Pre-clinical research compound. Not approved by FDA or any regulatory authority for human use.

SQ — abdomen. Rotate sites.

3. Timing

—

30–60 min pre-sleep.

4. Storage

—

Lyophilised: room temp. Reconstituted: refrigerate ≤30 days.

5. Needle

—

29–31G insulin syringe.